Korsana Biosciences, Inc. Common Stock
KRSA
14 hedge funds and large institutions have $3.58M invested in Korsana Biosciences, Inc. Common Stock in 2023 Q4 according to their latest regulatory filings, with 0 funds opening new positions, 3 increasing their positions, 5 reducing their positions, and 1 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 1 → 1 (0)
0.86% less ownership
Funds ownership: 44.52% → 43.65% (-0.86%)
2% less capital invested
Capital invested by funds: $3.66M → $3.58M (-$77.6K)
7% less funds holding
Funds holding: 15 → 14 (-1)
40% less repeat investments, than reductions
Existing positions increased: 3 | Existing positions reduced: 5
100% less first-time investments, than exits
New positions opened: 0 | Existing positions closed: 1
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tyndall Capital Partners
New York
|
+$6.9K |
| 2 |
UBS Group
Zurich,
Switzerland
|
+$807 |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
+$211 |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
-$7.04K |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$7K |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$702 |
| 4 |
BlackRock
New York
|
-$341 |
| 5 |
Royal Bank of Canada
Toronto,
Ontario, Canada
|
-$240 |
KRSA Hedge Fund Activity: Q4 2023 in Review
14 of the 6,870 institutional investors tracked by Wall St. Rank reported a position in Korsana Biosciences, Inc. Common Stock (KRSA) for Q4 2023, worth a combined $3.58M — down 2.1% from $3.66M a quarter earlier.
Sellers outnumbered buyers: 1 fund closed out of KRSA and 0 opened new positions — a net loss of 1 holder — while 5 trimmed existing stakes and 3 added.
The largest buyer was Tyndall Capital Partners, adding an estimated $6.9K. The largest seller was Vanguard Group, cutting an estimated $7.04K.
- 14 institutional investors held Korsana Biosciences, Inc. Common Stock (KRSA) as of Q4 2023, down from 15 in Q3 2023.
- Funds reported $3.58M of Korsana Biosciences, Inc. Common Stock stock for Q4 2023, down 2.1% quarter-over-quarter.
- 0 funds opened new Korsana Biosciences, Inc. Common Stock positions in Q4 2023 and 1 closed out, a net change of -1 holder.
- The largest Korsana Biosciences, Inc. Common Stock buyer in Q4 2023 was Tyndall Capital Partners, an estimated $6.9K added.
- The largest Korsana Biosciences, Inc. Common Stock seller in Q4 2023 was Vanguard Group, an estimated $7.04K sold.
Based on aggregated 13F filings for Q4 2023.